Deal or no deal?

In the 1980s and 90s, pharma companies swallowed up smaller biotech companies on a regular basis, acquiring new drug candidates, intellectual property and staff. That was then – now the landscape is different and pharma companies are as likely be partners with biotechs as they are predators. Collaboration and licensing deals are increasingly common, even between biotechs themselves.